Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hospitalized Clear all
Withdrawn Phase 4 Interventional

How Lidocaine Affects Outcomes In Orthopedic Surgery Patients

NCT01179100
View directory record Official record
Conditions
General Anesthesia, Surgeries Requiring A Minimum One Day Hospitalization, Elderly
Interventions
Lidocaine
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Not applicable Interventional

A Pilot Study to Examine Sleep and Fatigue in Pediatric Brain Tumor Patients Hospitalized for High Dose Chemotherapy

NCT00666614
View directory record Official record
Conditions
Sleep, Fatigue
Interventions
Sleep Environment Intervention, Normal Hospital Environment
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
4 Years to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Phase 2 Interventional

A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

NCT01966601
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
TRV027 Dose #1, TRV027 Dose #2, TRV027 Dose #3, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Detroit, Michigan • Cincinnati, Ohio • Tullahoma, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 7, 2026, 11:08 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

NCT04424901
View directory record Official record
Conditions
COVID-19 Pneumonia, Vascular Complications
Interventions
Placebo, Dipyridamole Tablets
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 7, 2026, 11:08 AM EDT
Terminated Not applicable Interventional Results available

Nasal High Flow Therapy 30 Day Readmission Study

NCT02552732
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
NHF with or without Oxygen
Device
Lead sponsor
Fisher and Paykel Healthcare
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Phase 4 Interventional

FREEDOM COVID-19 Anticoagulation Strategy

NCT04512079
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Valentin Fuster
Other
Eligibility
18 Years and older
Enrollment
3,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Phase 3 Interventional

The Congestive Heart Failure Adherence Redesign Trial

NCT01698242
View directory record Official record
Conditions
Heart Failure, Congestive, Cardiovascular Diseases, Heart Diseases
Interventions
Enhanced Training, Enhanced Education
Behavioral
Lead sponsor
Lynda Powell, PhD, MEd
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 7, 2026, 11:08 AM EDT
Withdrawn Not applicable Interventional

Ultrasound Guided Peripheral Intravenous Catheter Insertion in the Hospitalized Patient: Long vs. Short Axis Placement

NCT01870661
View directory record Official record
Conditions
Need for IV Access
Interventions
Long axis IV placement with ultrasound, Short axis IV placement with ultrasound
Device
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 7, 2026, 11:08 AM EDT
Not listed Phase 2 Interventional

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

NCT04840459
View directory record Official record
Conditions
Covid19
Interventions
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
Biological
Lead sponsor
Sohail Rao
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 7, 2026, 11:08 AM EDT
Active, not recruiting No phase listed Observational

Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study

NCT03098459
View directory record Official record
Conditions
Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma, Polytrauma, Traumatic Brain Injury, ICU, Critical Illness
Interventions
Non-interventional observational prospective cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 7, 2026, 11:08 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

NCT02579265
View directory record Official record
Conditions
Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Interventions
Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
0 Weeks and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
6,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

NCT04362176
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV-2
Interventions
pathogen reduced SARS-CoV-2 convalescent plasma, Placebo
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 7, 2026, 11:08 AM EDT
Terminated Phase 1 Interventional Results available

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

NCT03862040
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Cefiderocol, Standard of Care Antibiotic
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 7, 2026, 11:08 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

NCT03333317
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
Lumicitabine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 36 Months
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Long Beach, California • Kansas City, Missouri • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 7, 2026, 11:08 AM EDT
Withdrawn Phase 4 Interventional

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin

NCT00906529
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Levemir (Detemir) and Novolog (Aspart) Insulin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

NCT00663169
View directory record Official record
Conditions
Arthritis, Gouty
Interventions
canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone
Biological · Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 7, 2026, 11:08 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

NCT02927431
View directory record Official record
Conditions
Virus Diseases
Interventions
Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Sep 7, 2026, 11:08 AM EDT
Recruiting Phase 3 Interventional

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

NCT05354141
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS
Interventions
ExoFlo, Intravenous normal saline
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Davis, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 7, 2026, 11:08 AM EDT
Active, not recruiting Not applicable Interventional Results available

Pharmacist Intervention to Reduce Post-Hospitalization Utilization

NCT04071951
View directory record Official record
Conditions
Nonadherence, Patient, Polypharmacy, Readmission
Interventions
Pharmacist-led Hospital Discharge Care Intervention
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
55 Years and older
Enrollment
6,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 7, 2026, 11:08 AM EDT
Recruiting Not applicable Interventional

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

NCT03728166
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Phase 4 Interventional Results available

Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

NCT05292053
View directory record Official record
Conditions
Copd
Interventions
TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Not applicable Interventional

Disruptive bEhavior manageMEnt ANd Prevention in Hospitalized Patients Using a behaviORal Intervention Team

NCT03777241
View directory record Official record
Conditions
Behavioral Problem
Interventions
Behavioral Intervention Team, Standard of care
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 7, 2026, 11:08 AM EDT
Completed Not applicable Interventional

Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome

NCT00018837
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorder
Interventions
Community Re-Entry Program: What is Schizophrenia
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 7, 2026, 11:08 AM EDT